TY  - JOUR
AU  - Đurašević, Siniša
AU  - Nikolić, Gorana
AU  - Zaletel,  Ivan
AU  - Grigorov,  Ilijana
AU  - Memon, Lidija
AU  - Mitić-Ćulafić, Dragana
AU  - Vujović, Predrag
AU  - Đorđević, Jelena
AU  - Todorović, Zoran
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3519
AB  - Non-diabetic and alloxan-induced diabetic rats were fed with standard laboratory food enriched with 20% virgincoconut oil for 16 weeks. In non-diabetic animals coconut oil improved insulin sensitivity and ability to controlglycaemia and decreased the serum triglycerides for almost 50% in comparison with controls. Supplementationwith coconut oil caused liver steatosis in both non-diabetic and diabetic animals. However, the severity ofsteatosis was lower in diabetic animals compared to non-diabetic animals. Coconut oil had no effects on hearthistology, ascending and abdominal aorta wall thickening and atherosclerotic plaques development neither innon-diabetic nor in diabetic animals. While alloxan treatment caused Type I diabetes in rats, supplementationwith coconut oil in combination with the alloxan unexpectedly resulted in Type II diabetes. The development ofsevere insulin resistance and deterioration in serum lipid profile implied that the use of coconut oil is contra-indicated in diabetic condition.
PB  - Elsevier
T2  - Journal of Functional Foods
T1  - Distinct effects of virgin coconut oil supplementation on the glucose and lipid homeostasis in non-diabetic and alloxan-induced diabetic rats
VL  - 64
DO  - 10.1016/j.jff.2019.103601
ER  - 

@article{
author = "Đurašević, Siniša and Nikolić, Gorana and Zaletel,  Ivan and Grigorov,  Ilijana and Memon, Lidija and Mitić-Ćulafić, Dragana and Vujović, Predrag and Đorđević, Jelena and Todorović, Zoran",
year = "2020",
abstract = "Non-diabetic and alloxan-induced diabetic rats were fed with standard laboratory food enriched with 20% virgincoconut oil for 16 weeks. In non-diabetic animals coconut oil improved insulin sensitivity and ability to controlglycaemia and decreased the serum triglycerides for almost 50% in comparison with controls. Supplementationwith coconut oil caused liver steatosis in both non-diabetic and diabetic animals. However, the severity ofsteatosis was lower in diabetic animals compared to non-diabetic animals. Coconut oil had no effects on hearthistology, ascending and abdominal aorta wall thickening and atherosclerotic plaques development neither innon-diabetic nor in diabetic animals. While alloxan treatment caused Type I diabetes in rats, supplementationwith coconut oil in combination with the alloxan unexpectedly resulted in Type II diabetes. The development ofsevere insulin resistance and deterioration in serum lipid profile implied that the use of coconut oil is contra-indicated in diabetic condition.",
publisher = "Elsevier",
journal = "Journal of Functional Foods",
title = "Distinct effects of virgin coconut oil supplementation on the glucose and lipid homeostasis in non-diabetic and alloxan-induced diabetic rats",
volume = "64",
doi = "10.1016/j.jff.2019.103601"
}

Đurašević, S., Nikolić, G., Zaletel, I., Grigorov, I., Memon, L., Mitić-Ćulafić, D., Vujović, P., Đorđević, J.,& Todorović, Z.. (2020). Distinct effects of virgin coconut oil supplementation on the glucose and lipid homeostasis in non-diabetic and alloxan-induced diabetic rats. in Journal of Functional Foods
Elsevier., 64.
https://doi.org/10.1016/j.jff.2019.103601

Đurašević S, Nikolić G, Zaletel I, Grigorov I, Memon L, Mitić-Ćulafić D, Vujović P, Đorđević J, Todorović Z. Distinct effects of virgin coconut oil supplementation on the glucose and lipid homeostasis in non-diabetic and alloxan-induced diabetic rats. in Journal of Functional Foods. 2020;64.
doi:10.1016/j.jff.2019.103601 .

Đurašević, Siniša, Nikolić, Gorana, Zaletel,  Ivan, Grigorov,  Ilijana, Memon, Lidija, Mitić-Ćulafić, Dragana, Vujović, Predrag, Đorđević, Jelena, Todorović, Zoran, "Distinct effects of virgin coconut oil supplementation on the glucose and lipid homeostasis in non-diabetic and alloxan-induced diabetic rats" in Journal of Functional Foods, 64 (2020),
https://doi.org/10.1016/j.jff.2019.103601 . .

TY  - JOUR
AU  - Kostić, Vladimir
AU  - Džoljić, Eleonora
AU  - Todorović, Zoran
AU  - Mijajlović, Milija
AU  - Svetel, Marina
AU  - Stefanova, Elka
AU  - Dragašević, Nataša
AU  - Petrović, Igor
AU  - Milošević, Milenko
AU  - Kovačević, Ivan
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1825
AB  - Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted.
AB  - Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine
T1  - Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi
VL  - 69
IS  - 12
SP  - 1067
EP  - 1075
DO  - 10.2298/VSP111114028K
ER  - 

@article{
author = "Kostić, Vladimir and Džoljić, Eleonora and Todorović, Zoran and Mijajlović, Milija and Svetel, Marina and Stefanova, Elka and Dragašević, Nataša and Petrović, Igor and Milošević, Milenko and Kovačević, Ivan and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica",
year = "2012",
abstract = "Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted., Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine, Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi",
volume = "69",
number = "12",
pages = "1067-1075",
doi = "10.2298/VSP111114028K"
}

Kostić, V., Džoljić, E., Todorović, Z., Mijajlović, M., Svetel, M., Stefanova, E., Dragašević, N., Petrović, I., Milošević, M., Kovačević, I., Miljković, B., Pokrajac, M.,& Prostran, M.. (2012). Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 69(12), 1067-1075.
https://doi.org/10.2298/VSP111114028K

Kostić V, Džoljić E, Todorović Z, Mijajlović M, Svetel M, Stefanova E, Dragašević N, Petrović I, Milošević M, Kovačević I, Miljković B, Pokrajac M, Prostran M. Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled. 2012;69(12):1067-1075.
doi:10.2298/VSP111114028K .

Kostić, Vladimir, Džoljić, Eleonora, Todorović, Zoran, Mijajlović, Milija, Svetel, Marina, Stefanova, Elka, Dragašević, Nataša, Petrović, Igor, Milošević, Milenko, Kovačević, Ivan, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine" in Vojnosanitetski pregled, 69, no. 12 (2012):1067-1075,
https://doi.org/10.2298/VSP111114028K . .

TY  - JOUR
AU  - Vezmar, Sandra
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Timotijević, Ivana
AU  - Prostran, Milica
AU  - Todorović, Zoran
AU  - Pokrajac, Milena
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1232
AB  - Although often necessary for obtaining remission following major depressive disorder, combined antidepressant treatment Is frequently associated with drug interactions and enhanced adverse drug effects. We investigated pharmacokinetic interactions following combined fluvoxamine and amitriptyline treatment and their impact on therapeutic efficacy and tolerability. Twenty-two inpatients with major depression [Hamilton Depression Scale (HAM-D) rating >= 18] were treated with either amitriptyline (75 mg/day), fluvoxamine (100 mg/day) or both. Blood samples, for determination of amitriptyline, its major metabolite nortritpyline, and fluvoxamine, were obtained after single dose administration and in steady-state. Therapeutic efficacy was evaluated using HAM-D and adverse drug effects were evaluated using the clinical global impression scale. Following combined treatment, steady-state plasma levels of nortriptyline were significantly decreased compared to monotherapy. HAM-D scores after two-week treatment showed that there was a better response to combined treatment. There was no significant difference in severity of adverse effects among groups. We observed a pharmcokinetic interaction between fluvoxamine and amitritpyline resulting in impaired metabolism of the later. However, no signifcant impact of the interaction on treatment safety was observed. Moreover, concomitant use of amitriptyline at 75mg/day and fluvoxamine at 100 mg/day was well tolerated with a more prompt and stronger onset of clinical response compared to monotherapy in patients with major depression.
PB  - Japanese Pharmacological Soc, Kyoto
T2  - Journal of Pharmacological Sciences
T1  - Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression
VL  - 110
IS  - 1
SP  - 98
EP  - 104
DO  - 10.1254/jphs.09013FP
ER  - 

@article{
author = "Vezmar, Sandra and Miljković, Branislava and Vučićević, Katarina and Timotijević, Ivana and Prostran, Milica and Todorović, Zoran and Pokrajac, Milena",
year = "2009",
abstract = "Although often necessary for obtaining remission following major depressive disorder, combined antidepressant treatment Is frequently associated with drug interactions and enhanced adverse drug effects. We investigated pharmacokinetic interactions following combined fluvoxamine and amitriptyline treatment and their impact on therapeutic efficacy and tolerability. Twenty-two inpatients with major depression [Hamilton Depression Scale (HAM-D) rating >= 18] were treated with either amitriptyline (75 mg/day), fluvoxamine (100 mg/day) or both. Blood samples, for determination of amitriptyline, its major metabolite nortritpyline, and fluvoxamine, were obtained after single dose administration and in steady-state. Therapeutic efficacy was evaluated using HAM-D and adverse drug effects were evaluated using the clinical global impression scale. Following combined treatment, steady-state plasma levels of nortriptyline were significantly decreased compared to monotherapy. HAM-D scores after two-week treatment showed that there was a better response to combined treatment. There was no significant difference in severity of adverse effects among groups. We observed a pharmcokinetic interaction between fluvoxamine and amitritpyline resulting in impaired metabolism of the later. However, no signifcant impact of the interaction on treatment safety was observed. Moreover, concomitant use of amitriptyline at 75mg/day and fluvoxamine at 100 mg/day was well tolerated with a more prompt and stronger onset of clinical response compared to monotherapy in patients with major depression.",
publisher = "Japanese Pharmacological Soc, Kyoto",
journal = "Journal of Pharmacological Sciences",
title = "Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression",
volume = "110",
number = "1",
pages = "98-104",
doi = "10.1254/jphs.09013FP"
}

Vezmar, S., Miljković, B., Vučićević, K., Timotijević, I., Prostran, M., Todorović, Z.,& Pokrajac, M.. (2009). Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression. in Journal of Pharmacological Sciences
Japanese Pharmacological Soc, Kyoto., 110(1), 98-104.
https://doi.org/10.1254/jphs.09013FP

Vezmar S, Miljković B, Vučićević K, Timotijević I, Prostran M, Todorović Z, Pokrajac M. Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression. in Journal of Pharmacological Sciences. 2009;110(1):98-104.
doi:10.1254/jphs.09013FP .

Vezmar, Sandra, Miljković, Branislava, Vučićević, Katarina, Timotijević, Ivana, Prostran, Milica, Todorović, Zoran, Pokrajac, Milena, "Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression" in Journal of Pharmacological Sciences, 110, no. 1 (2009):98-104,
https://doi.org/10.1254/jphs.09013FP . .

TY  - JOUR
AU  - Todorović, Zoran
AU  - Džoljić, Eleonora
AU  - Novaković, Ivana
AU  - Mirković, Duško
AU  - Stojanović, Radan
AU  - Nesić, Zorica
AU  - Krajinović, Maja
AU  - Prostran, Milica
AU  - Kostić, Vladimir
PY  - 2006
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/666
AB  - Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.
PB  - Elsevier Science BV, Amsterdam
T2  - Journal of the Neurological Sciences
T1  - Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy
VL  - 248
IS  - 1-2
SP  - 56
EP  - 61
DO  - 10.1016/j.jns.2006.05.040
ER  - 

@article{
author = "Todorović, Zoran and Džoljić, Eleonora and Novaković, Ivana and Mirković, Duško and Stojanović, Radan and Nesić, Zorica and Krajinović, Maja and Prostran, Milica and Kostić, Vladimir",
year = "2006",
abstract = "Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa treatment may give rise to elevated serum homocysteine levels in parkinsonian patients. We aimed to clarify the interplay of these factors in pathogenesis of Parkinson's disease (PD)-related hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and MTHFR C677T genotype were investigated in levodopa-treated and -untreated parkinsonian ("de novo") patients, as well as in control healthy subjects matched by age and gender (N=83, 30 and 53, respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed in app. 12-17% cases. tHcy concentrations were significantly higher in both levodopa-treated and -untreated PD patients than in control subjects, and in TT homozygotes than in CT or CC genotype carriers. tHcy levels significantly correlated with the duration of the disease in PD treated patients only, reaching the maximum after 3-6 years. However, there was no correlation between tHcy levels and total daily intake of levodopa in the same group of PD patients. In conclusion, MTHFR C677T genotype is a significant factor for hyperhomocysteinemia. in patients with PD, levodopa-untreated and probably even more in levodopa-treated PD patients.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Journal of the Neurological Sciences",
title = "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy",
volume = "248",
number = "1-2",
pages = "56-61",
doi = "10.1016/j.jns.2006.05.040"
}

Todorović, Z., Džoljić, E., Novaković, I., Mirković, D., Stojanović, R., Nesić, Z., Krajinović, M., Prostran, M.,& Kostić, V.. (2006). Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences
Elsevier Science BV, Amsterdam., 248(1-2), 56-61.
https://doi.org/10.1016/j.jns.2006.05.040

Todorović Z, Džoljić E, Novaković I, Mirković D, Stojanović R, Nesić Z, Krajinović M, Prostran M, Kostić V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. in Journal of the Neurological Sciences. 2006;248(1-2):56-61.
doi:10.1016/j.jns.2006.05.040 .

Todorović, Zoran, Džoljić, Eleonora, Novaković, Ivana, Mirković, Duško, Stojanović, Radan, Nesić, Zorica, Krajinović, Maja, Prostran, Milica, Kostić, Vladimir, "Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy" in Journal of the Neurological Sciences, 248, no. 1-2 (2006):56-61,
https://doi.org/10.1016/j.jns.2006.05.040 . .